DK2056842T3 - Modificeret galactosylceramid til behandling af cancerøse sygdomme - Google Patents

Modificeret galactosylceramid til behandling af cancerøse sygdomme

Info

Publication number
DK2056842T3
DK2056842T3 DK07760333.0T DK07760333T DK2056842T3 DK 2056842 T3 DK2056842 T3 DK 2056842T3 DK 07760333 T DK07760333 T DK 07760333T DK 2056842 T3 DK2056842 T3 DK 2056842T3
Authority
DK
Denmark
Prior art keywords
galactosylceramide
modified
treatment
cancerous diseases
cancerous
Prior art date
Application number
DK07760333.0T
Other languages
English (en)
Inventor
Paul B Savage
Luc Teyton
Albert Bendelac
Original Assignee
Univ Chicago
Scrips Res Inst
Univ Brigham Young
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago, Scrips Res Inst, Univ Brigham Young filed Critical Univ Chicago
Application granted granted Critical
Publication of DK2056842T3 publication Critical patent/DK2056842T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK07760333.0T 2006-04-07 2007-04-09 Modificeret galactosylceramid til behandling af cancerøse sygdomme DK2056842T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79009606P 2006-04-07 2006-04-07
PCT/US2007/066250 WO2007118234A2 (en) 2006-04-07 2007-04-09 Modified -galactosyl ceramides for staining and stimulating natural killer t cells

Publications (1)

Publication Number Publication Date
DK2056842T3 true DK2056842T3 (da) 2013-01-14

Family

ID=38581864

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07760333.0T DK2056842T3 (da) 2006-04-07 2007-04-09 Modificeret galactosylceramid til behandling af cancerøse sygdomme

Country Status (12)

Country Link
US (2) US8227581B2 (da)
EP (1) EP2056842B1 (da)
AU (1) AU2007234753B2 (da)
BR (1) BRPI0710668A2 (da)
CA (1) CA2661789C (da)
DK (1) DK2056842T3 (da)
ES (1) ES2397975T3 (da)
PL (1) PL2056842T3 (da)
PT (1) PT2056842E (da)
SI (1) SI2056842T1 (da)
WO (1) WO2007118234A2 (da)
ZA (1) ZA200900905B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
DK1848813T3 (da) 2005-01-28 2013-07-15 Univ Brigham Young Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
AU2013202865B2 (en) * 2007-11-07 2015-03-19 Abivax Increase of immune response and targeting by antigens and/or drug linkage
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
BRPI0820960B8 (pt) * 2007-12-05 2021-05-25 Abivax composição, composição farmacêutica, e uso da composição
US9220767B2 (en) * 2008-10-08 2015-12-29 Abivax Vaccine composition for use against influenza
ES2345377B1 (es) * 2009-03-20 2011-07-21 Consejo Superior De Investigaciones Cientificas (Csis) (51%) Compuestos aminociclitoles, procedimiento de obtencion y usos.
US8835613B2 (en) 2010-03-12 2014-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
MY171201A (en) 2012-04-26 2019-10-01 Riken New carbamate glycolipid and use thereof
US9321796B2 (en) 2012-06-28 2016-04-26 Universiteit Gent Galactopyranosyl derivatives useful as medicaments
EP2727929A1 (en) * 2012-10-30 2014-05-07 Wittycell Method of preparation of alpha galactosyl ceramides compounds
US20170029454A1 (en) * 2013-06-28 2017-02-02 The Scripps Research Institute Nkt cell ligands and methods of use
US10046046B2 (en) * 2014-06-05 2018-08-14 Victoria Link Limited Amino sphingoglycolipid analogues
WO2018050782A1 (en) 2016-09-14 2018-03-22 Abivax Combinations including abx196 for the treatment of cancer
WO2019190986A1 (en) * 2018-03-26 2019-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 3-o-sulfo-galactosylceramide analogs as activators of type ii nkt cells and uses thereof
WO2023121483A1 (en) * 2021-12-24 2023-06-29 Victoria Link Limited Immunostimulatory compositions
CN115286667B (zh) * 2022-08-02 2024-03-26 华中农业大学 一种α-半乳糖基神经酰胺类似物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242800A (en) * 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (da) * 1992-07-16 1995-11-01 Kirin Brewery
ATE191916T1 (de) * 1992-10-22 2000-05-15 Kirin Brewery Neues sphingolglycolipid und verwendung davon
US5780441A (en) * 1993-04-15 1998-07-14 Kirin Beer Kabushiki Kaisha Sphingoglycolipid compounds and therapeutic uses thereof
CN1125449A (zh) * 1993-05-14 1996-06-26 萨依特尔有限公司 作为细胞粘附抑制剂的唾液基Lex类似物
US6054433A (en) * 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) * 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
US6417167B1 (en) * 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
AU739673B2 (en) 1997-02-05 2001-10-18 Kirin Pharma Kabushiki Kaisha Lyophilized compositions containing sphingoglycolipid and process for preparing them
EP1520583B1 (en) * 1997-04-10 2009-01-28 Kyowa Hakko Kirin Co., Ltd. NKT cell-activating agents containing alpha-glycosylceramides
CA2316041A1 (en) 1997-12-30 1999-07-08 Pam Fredman Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
EP1053243B1 (en) * 1998-02-12 2011-03-30 Emory University Sphingolipid derivatives and their methods of use
US20030157113A1 (en) * 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
US20030153514A1 (en) * 2000-04-28 2003-08-14 Akikuni Yagita Remedies for cancer
JP4410913B2 (ja) * 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
AU2001286636A1 (en) * 2000-08-25 2002-03-13 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
CN1578667A (zh) * 2001-11-06 2005-02-09 东方癌症治疗株式会社 抗癌组合物
US7273853B2 (en) * 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
WO2003105769A2 (en) 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
WO2004094444A1 (en) * 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
US7645873B2 (en) * 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
CA2560969A1 (en) * 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
AU2005280163B2 (en) 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
DK1786439T3 (da) * 2004-09-03 2010-07-12 Univ Chicago Fremgangsmåder til aktivering af NKT-celler
JP5090928B2 (ja) * 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Ｎｋｔ細胞に対する抗原としての糖脂質及びその類似体
DK1848813T3 (da) 2005-01-28 2013-07-15 Univ Brigham Young Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
BRPI0617687A2 (pt) 2005-10-25 2011-08-02 Ludwig Inst Cancer Res composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica
AU2007269299B2 (en) * 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells

Also Published As

Publication number Publication date
CA2661789C (en) 2014-06-03
US20120270815A1 (en) 2012-10-25
ES2397975T3 (es) 2013-03-12
PT2056842E (pt) 2013-01-24
BRPI0710668A2 (pt) 2011-08-16
WO2007118234A3 (en) 2007-12-06
PL2056842T3 (pl) 2013-03-29
AU2007234753B2 (en) 2013-02-21
WO2007118234A2 (en) 2007-10-18
US20090047299A1 (en) 2009-02-19
EP2056842B1 (en) 2012-10-17
CA2661789A1 (en) 2007-10-18
ZA200900905B (en) 2010-06-30
SI2056842T1 (sl) 2013-02-28
US8227581B2 (en) 2012-07-24
EP2056842A2 (en) 2009-05-13
US8765692B2 (en) 2014-07-01
EP2056842A4 (en) 2010-10-06
AU2007234753A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK3457135T3 (da) Behandlingsmuligheder til fabrys sygdom
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0821779A2 (pt) tratamento terapêutico de câncer
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2047863T3 (da) Middel til forebyggelse eller behandling af inflammatoriske sygdomme
DK2121139T3 (da) Formulations for cancer treatment
ZA201001304B (en) Compositions for the treatment of neoplastic diseases
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
DK2035369T3 (da) Terapeutiske
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
PL2056842T3 (pl) Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2022504T3 (da) Salve til behandling af hæmorider
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom